What question did this study set out to answer?

This research aims to assess the long-term effectiveness of antipsychotic treatment on functional outcomes in individuals with schizophrenia over a decade.

June 19, 2026Open Access

Real-world effectiveness of antipsychotic treatment of functional outcomes over 10 years: A national cohort of patients in Denmark with schizophrenia

Key Points

This research aims to assess the long-term effectiveness of antipsychotic treatment on functional outcomes in individuals with schizophrenia over a decade.
Nationwide register-based cohort study of 65,630 individuals with schizophrenia in Denmark (1998-2023)
Utilized within-subject stratified Cox models and Fine-Gray competing risks models for analysis
Focused on productive engagement as a primary outcome, measuring employment or education status.
Overall productive engagement rate was 48.2% across the study period
Medication use reduced engagement rates during the acute (HR = 0.908) and consolidation phases (HR = 0.946), but showed a slight increase in the maintenance phase (HR = 1.019)
The Fine-Gray model produced a cumulative engagement SHR of 1.002 (95% CI = 0.988-1.015) highlighting varied effects across different phases.

Abstract

BACKGROUND: Antipsychotic medications are recommended for schizophrenia spectrum disorders, yet their long-term effects on functional recovery remain unclear, with conflicting evidence often derived from between-subject comparisons vulnerable to confounding by indication. METHODS: We conducted a nationwide register-based cohort study of 65,630 individuals with incident schizophrenia spectrum disorders in Denmark (1998-2023). We modeled antipsychotic exposure against 'productive engagement' (employment or education). We used two analytical approaches: (1) within-subject stratified Cox models with time-varying covariates to eliminate time-invariant confounding; and (2) Fine-Gray competing risks models with baseline exposure, accounting for mortality and emigration. RESULTS: Over 26.9 million person-weeks, the overall productive engagement rate was 48.2%. Integration of hospital pharmacy data revealed 6.1% exposure misclassification in studies relying solely on community records. The primary within-subject analysis revealed significant temporal heterogeneity: medication use was associated with reduced engagement rates in the acute (0-2 years; HR = 0.908) and consolidation phases (2-5 years; HR = 0.946), but reversed to a small positive association in the maintenance phase (5+ years; HR = 1.019). The between-subject Fine-Gray model, which estimates cumulative engagement probabilities, yielded an SHR of 1.002 (95% CI = 0.988-1.015), a population-level average that obscured these phase-specific dynamics. CONCLUSIONS: Antipsychotic pharmacotherapy exerts a time-dependent, biphasic impact on vocational recovery. We identified a window of vulnerability during the post-acute 'consolidation' phase (years 2-5) where treatment is associated with a transient reduction in productive engagement, before becoming protective after 5 years. These findings challenge the assumption that symptomatic stability automatically facilitates functional reintegration.

Bookmark

View Full Paper